Cognetivity Neurosciences Ltd.

DB:1UB Stock Report

Market Cap: €625.2k

Cognetivity Neurosciences Valuation

Is 1UB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1UB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1UB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1UB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1UB?

Key metric: As 1UB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1UB. This is calculated by dividing 1UB's market cap by their current revenue.
What is 1UB's PS Ratio?
PS Ratio9.5x
SalesCA$98.97k
Market CapCA$935.57k

Price to Sales Ratio vs Peers

How does 1UB's PS Ratio compare to its peers?

The above table shows the PS ratio for 1UB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.2x
AUG Audientes
12.6xn/a€6.9m
GME Geratherm Medical
1x1.9%€21.0m
AAQ1 aap Implantate
1.9xn/a€22.4m
MTN Milton Essex Spólka Akcyjna
9.3xn/azł6.2m
1UB Cognetivity Neurosciences
9.5xn/a€935.6k

Price-To-Sales vs Peers: 1UB is expensive based on its Price-To-Sales Ratio (9.5x) compared to the peer average (1.6x).

Price to Sales Ratio vs Industry

How does 1UB's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$830.14m
PHH2 Paul Hartmann
0.3xn/aUS$781.42m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
1UB 9.5xIndustry Avg. 3.6xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1UB is expensive based on its Price-To-Sales Ratio (9.5x) compared to the European Medical Equipment industry average (3.8x).

Price to Sales Ratio vs Fair Ratio

What is 1UB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1UB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1UB's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sensus Healthcare

US$143.9m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$8.25

7D

4.4%

1Y

263.8%

Shandong Weigao Group Medical Polymer

HK$20.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.9%

1Y

-37.7%

LNA Santé

€240.3m

Engages in the management and operation of health establishments.

2N3

€23.00

7D

1.5%

1Y

17.7%